Related coverage linked through entity extraction aliases.
Aug 05, 2026
Insilico Medicine named ISM9528 as its 31st AI-driven preclinical pain candidate, published a target discovery study for a rare sinonasal cancer, and advanced partnerships with MSK and Takeda. The company is also presenting oncology programs at AACR 2026.
Jun 10, 2026
Twenty years after HPV vaccine approval, head and neck cancers have become the most common HPV-related cancer with 16,000 cases annually. The incidence tripled from 2000 to 2017, primarily affecting men in their 40s to 60s. Vaccination rates among teens reached approximately 77-79% for at least one dose in 2024.
Apr 24, 2026
Yale Cancer Center experts presented research at the 2026 AACR Annual Meeting in San Diego, including patient-centered trials, pathology methods and head and neck cancer studies. The meeting also included a plenary presentation, a pathology award and an AACR Trailblazer Cancer Research Grant.
Apr 01, 2026
Patient-derived organoids demonstrate clinically meaningful predictive value in drug development, with validation studies showing concordance between organoid drug-response profiles and patient outcomes. These models enable earlier go/no-go decisions and more rational clinical trial design, as evidenced by their use in developing FDA Breakthrough Therapy designated candidates.
Mar 11, 2026
AstraZeneca terminated its Phase I/IIa trial of AZD0022 for KRASG12D-mutant cancers, withdrew a planned saruparib ovarian cancer platform study, and completed a real-world non-small cell lung cancer treatment review.
Feb 14, 2026
New research and precision radiation techniques aim to minimize debilitating side effects of head and neck cancer treatment, including oral mucositis, while maintaining tumor control and improving patient quality of life.
